+20.0%
GE vs MRNA
+511.3%
-491.3%
-20.9%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 1y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | +1.1% | -2.2% | +3.3% | +1.1% |
| 7D | -1.6% | +5.5% | -7.1% | -1.6% |
| 30D | -11.6% | +158.7% | -170.3% | -11.1% |
| 3M | +3.0% | +182.1% | -179.1% | +2.2% |
| 6M | -0.5% | +151.8% | -152.3% | -0.8% |
| YTD | +9.7% | +393.6% | -383.8% | +3.9% |
| 1Y | +20.0% | +499.5% | -479.4% | +13.6% |
| All | +20.0% | +511.3% | -491.3% | +13.6% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 1y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
1y analysis · Full analysis span regression · 6 months rolling